Showing results (161-170 of 230) with videos related to
Sort By:
Pageof 23
EJNMMI Research|June 27, 2012
Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patientsBrenda F Kurland, Vijayakrishna K Gadi, Jennifer M Specht, et al.Journal of Magnetic Resonance Imaging : JMRI|October 30, 2010
Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancerSavannah C Partridge, Risa K Vanantwerp, Robert K Doot, et al.Molecular Imaging and Biology|October 31, 2013
A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC)Lanell M Peterson, Brenda F Kurland, Erin K Schubert, et al.Breast Cancer Research : BCR|November 10, 2023
Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancerAnum S Kazerouni, Lanell M Peterson, Isaac Jenkins, et al.JAMA Network Open|March 23, 2021
Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine TumorsSarit T Kipnis, Matthew Hung, Shria Kumar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2007
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphomaAjay K Gopal, Joseph G Rajendran, Ted A Gooley, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 12, 2025
Dual-Tracer Imaging on a Long-Axial-Field-of-View PET: A Proof-of-Principle Study with [18F]FGln and [18F]FDGDaniel Kwon, Elizabeth J Li, Christina Dulal, et al.Radiographics : a Review Publication of the Radiological Society of North America, Inc|January 18, 2002
Detection of locoregional and distant recurrences in breast cancer patients by using FDG PETWilliam B Eubank, David A Mankoff, Hubert J Vesselle, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2014
Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood-Brain Barrier, Is Compromised in Patients with Mild Alzheimer DiseaseAnand K Deo, Soo Borson, Jeanne M Link, et al.The Oncologist|March 7, 2020
Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor CohortJason M Heckert, Sarit T Kipnis, Shria Kumar, et al.Pageof 23